Skip to main content

Heart Transplant Failure and Rejection

0
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Natera
NateraAUSTIN, TX
2 programs
Prospera Transplant AssessmentN/A1 trial
The Prospera™ TestN/A1 trial
Active Trials
NCT05081739Withdrawn0Est. Jan 2026
NCT06414603Active Not Recruiting250Est. Feb 2027
Verona Pharma
Verona PharmaUK - London
1 program
PCI and implantation drug eluting stent or bare metal stentN/A1 trial
Active Trials
NCT03538509Unknown150Est. Oct 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
NateraThe Prospera™ Test
NateraProspera Transplant Assessment
Verona PharmaPCI and implantation drug eluting stent or bare metal stent

Clinical Trials (3)

Total enrollment: 400 patients across 3 trials

NCT06414603NateraThe Prospera™ Test

A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy

Start: Jun 2024Est. completion: Feb 2027250 patients
N/AActive Not Recruiting
NCT05081739NateraProspera Transplant Assessment

Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation

Start: Jan 2023Est. completion: Jan 20260
N/AWithdrawn
NCT03538509Verona PharmaPCI and implantation drug eluting stent or bare metal stent

Percutaneous Coronary Intervention in Patients witH OrthotoPic hEart Transplantation: the PCI-HOPE a Multicenter Study.

Start: Jan 2000Est. completion: Oct 2018150 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.